BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2011

View Archived Issues

OTS-11101 is well tolerated in first-in-human study in solid tumors

Read More

LY-2523355 advances in phase I trial in advanced/metastatic malignancies

Read More

Merck & Co. prepares novel adenosine A2A receptor antagonists

Read More

Genosco and Oscotec disclose new protein kinase inhibitors

Read More

Sirtris Pharmaceuticals presents new SIRT1 activators

Read More

Bristol-Myers Squibb patents new lysophospholipid S1P1 receptor agonists

Read More

EPI-743, a natural metabolite and orphan drug in inherited mitochondrial respiratory chain diseases

Read More

Metreleptin shows promise in partial lipodystrophy and amenorrhea

Read More

FDA accepts Adamis Pharmaceuticals' IND for APC-100 for prostate cancer

Read More

Phase I trial of Medicago's H1N1 flu vaccine shows safety and solid immune response

Read More

New putative biomarkers of systemic sclerosis identified

Read More

Bristol-Myers Squibb designs new series of HCV NS5A inhibitors

Read More

Scientists at Lilly describe novel opioid NOP receptor antagonists

Read More

Bionomics and Merck Serono extend MS collaboration

Read More

Forest Laboratories to launch Daliresp in U.S. this month

Read More

Two Morphotek products obtain FDA orphan drug status

Read More

FDA grants orphan drug status to Aradigm's ciprofloxacin for inhalation in bronchiectasis

Read More

Emergent BioSolutions' anthrax vaccine NuThrax gets FDA fast track status

Read More

First part of ivacaftor/VX-809 phase II trial in cystic fibrosis meets primary endpoints

Read More

Roche to make first milestone payment to Evolva in drug discovery collaboration

Read More

Synthes and Eli Lilly sign agreement focused on osteoporosis and bone fractures

Read More

Chugai provides update on application in Japan for Epogin in chemotherapy-induced anemia

Read More

Cell Therapeutics meets with FDA to discuss resubmission of pixantrone NDA

Read More

FDA approves Potiga as adjunctive treatment for partial-onset seizures

Read More

French and German authorities suspend use of pioglitazone-containing products

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 8, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • China compass

    ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

    BioWorld
    If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • Woman taking medication for mental illness

    Autobahn on the fast track with bipolar thyroid agonist

    BioWorld
    Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing